Announced details
Treatment of Hunter syndrome (mucopolysaccharidosis type II); sales and distribution in the MENA (Middle East and North Africa) region
Sold in Japan since May 2021. Kuwait is the second country outside Japan to grant approval.
The company has entered into a distribution agreement covering the MENA region.
Headquartered in the United Arab Emirates. CEO: Saif Al Hasani. The company is responsible for the marketing, sales and distribution of treatments for rare diseases in the MENA region. It has built 20-year relationships with clinicians, healthcare institutions and global partner companies.
Kuwait’s regulatory authority (name: Not disclosed)
The impact on consolidated results for the fiscal year ending March 2027 will be immaterial.
The company does not address Contract Value / Offering price.
Based on the company’s research; 6 papers published in Mol. Ther. and Int. J. Mol. Sci. are cited as reference literature
| Item | Details |
|---|---|
| Names of Products / Services Covered | Izkargo® (generic name: pabinafusp alfa; development code: JR-141), J-Brain Cargo® |
| Counterparty | Taiba Middle East FZ LLC |
| Counterparty overview | Headquartered in the United Arab Emirates. CEO: Saif Al Hasani. The company is responsible for the marketing, sales and distribution of treatments for rare diseases in the MENA region. It has built 20-year relationships with clinicians, healthcare institutions and global partner companies. |
| Relationship with the Company | The company has entered into a distribution agreement covering the MENA region. |
| Applicable area | Treatment of Hunter syndrome (mucopolysaccharidosis type II); sales and distribution in the MENA (Middle East and North Africa) region |
| Awarding / certifying body | Kuwait’s regulatory authority (name: Not disclosed) |
| Usage history | Sold in Japan since May 2021. Kuwait is the second country outside Japan to grant approval. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 will be immaterial. |
| Source | Based on the company’s research; 6 papers published in Mol. Ther. and Int. J. Mol. Sci. are cited as reference literature |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is pursuing approval under a distribution agreement with Taiba to leverage the marketing approval already obtained in Japan and develop its business in the MENA region. It also aims to expand treatment options for patients with Hunter syndrome, a rare disease.